Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products in the field of urology. Aytu is initially concentrating on hypogonadism (low testosterone), male infertility, and sexual wellness and vitality, and the company plans to expand into other urological indications for which there are significant medical needs. The company currently markets Natesto, the only FDA-approved nasally-administered testosterone, which is indicated for the treatment of hypogonadism. Outside the U.S., Aytu also markets the companyÍs proprietary MiOXSYS system, a novel, point-of-care diagnostic system with the potential to become a standard of care as an aid in the diagnosis of male infertility. MiOXSYS is CE Marked and Health Canada approved and has been sold in over 20 countries around the world. Aytu also markets ProstaScint, an FDA-approved radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. Aytu also now owns wholly-owned subsidiary Aytu Women's Health (formerly Nuelle), a personal health and wellness company focused on womenÍs sexual wellbeing and intimacy that markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal and sexual desire.